NASDAQ:PTGX | Free Cash Flow | Protagonist Therapeutics, Inc

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2014-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$48.94M$215,000.00-$49.16M-1299.44%
2025-12-31-$36.98M$144,000.00-$37.12M
2025-03-31$125.36M$545,000.00$124.82M
2024-12-31-$29.18M$310,000.00-$29.49M-22.39%
2024-03-31-$27.43M$242,000.00-$27.67M-13.35%
2023-12-31$16.96M$19,000.00$16.94M61.98%
2023-03-31-$34.35M$10,000.00-$34.36M
2022-12-31-$31.64M$70,000.00-$31.71M
2022-03-31-$37.67M$273,000.00-$37.94M
2021-12-31-$26.94M$196,000.00-$27.14M
2021-03-31-$28.76M$140,000.00-$28.9M
2020-12-31-$18.87M$125,000.00-$18.99M
2020-03-31-$15.85M$138,000.00-$15.99M
2019-12-31-$14.29M$218,000.00-$14.51M
2019-03-31-$16.66M$166,000.00-$16.83M
2018-12-31-$10.14M$62,000.00-$10.2M
2018-03-31-$15.14M$208,000.00-$15.35M
2017-12-31-$14.15M$56,000.00-$14.21M
2017-03-31-$10.36M$48,000.00-$10.4M
2016-12-31-$9.68M$52,000.00-$9.73M
2016-03-31-$5.24M$251,000.00-$5.49M
2015-12-31-$4.74M$220,000.00-$4.96M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$57.67M$1.59M$56.08M
2024-12-31$184.15M$1.36M$182.8M66.43%
2023-12-31-$70.24M$609,000.00-$70.85M
2022-12-31-$108.14M$795,000.00-$108.93M
2021-12-31-$107.87M$1.1M-$108.97M
2020-12-31-$72.48M$471,000.00-$72.96M
2019-12-31-$41.53M$967,000.00-$42.49M
2018-12-31-$49.95M$486,000.00-$50.43M
2017-12-31$3.87M$666,000.00$3.21M
2016-12-31-$29.97M$347,000.00-$30.32M
2015-12-31-$14.39M$399,000.00-$14.78M
2014-12-31-$7.74M$299,000.00-$8.04M